Wall Street Set for Rebound After Another Omicron Slump
9:18AM ET 12/01/2021 MT NewswiresUS stocks were set for a higher open Wednesday, recovering from a slump in the previous session amid concerns about the COVID-19 omicron variant and...
Quotes Snapshot > BTAI
BioXcel Therapeutics Inc BTAI:NASDAQ
Last Price$20.95NASDAQ Previous Close - Last Trade as of 4:00PM ET 12/06/21
Today's Change-0.51(2.38%)
Bid (Size)$19.19 (1)
Ask (Size)$23.23 (1)
Day Low / High$20.20 - 21.32
Volume281.1 K
Read more news Recent News
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday
9:13AM ET 12/01/2021 MT NewswiresHealth care stocks were edging higher premarket Wednesday as the iShares NASDAQ Biotechnology Index (IBB) was up 0.50% and the Health Care SPDR (XLV) was...
FDA Extends Review of BioXcel Therapeutics' BXCL501; Shares Tumble Pre-Bell
8:19AM ET 12/01/2021 MT NewswiresBioXcel Therapeutics (BTAI) reported that the US Food and Drug Administration has extended the Prescription Drug User Fee Act date for its review of the...
Top Premarket Decliners
8:11AM ET 12/01/2021 MT NewswiresAditxt (ADTX) shares slumped 21% after the company launched an underwritten public offering of common stock and warrants. BioXcel Therapeutics (BTAI)...
View all Commentary and Analysis
BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q3 2021 Results - Earnings Call Transcript
12:25PM ET 11/10/2021 Seeking AlphaBioXcel Therapeutics: Ready To Enter The Depression Therapeutic Field
3:48AM ET 10/24/2021 Seeking AlphaBioXcel Therapeutics (BTAI) Investor Presentation - Slideshow
1:22PM ET 10/07/2021 Seeking AlphaBioXcel: Recent Selloff Offers A Very Good Opportunity To Entry At A Discount Price
2:32PM ET 8/18/2021 Seeking AlphaCompany Profile
Business DescriptionBioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on drug development. The firm's two clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT. View company web site for more details
| Address | 555 Long Wharf Drive New Haven, Connecticut 06511 |
| Phone | +1.475.238.6837 |
| Number of Employees | 18 |
| Recent SEC Filing | 12/02/2021 8-K |
| President, Chief Executive Officer & Director | Vimal D. Mehta |
| Chief Financial Officer & Vice President | Richard I. Steinhart |
| Chief Scientific Officer & Senior Vice President | Frank D. Yocca |
| Chief Medical Officer & Senior Vice President | Vincent J. O'Neill |
Company Highlights
| Price Open | $21.22 |
| Previous Close | $20.95 |
| 52 Week Range | $18.82 - 67.74 |
| Market Capitalization | $586.2 M |
| Shares Outstanding | 28.0 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 03/10/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$4.00 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | N/A |
| Return on Equity | -44.97% |
Analyst Ratings as of 12/06/2021
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |